{"disease":{"id":"elevated-lipoprotein-a","name":"elevated lipoprotein a"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06014060","title":"24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":3300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT03070782","title":"Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT06420817","title":"Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jubilee Mission Medical College and Research Institute","has_results":false},{"nct_id":"NCT04987320","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03426033","title":"Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Akcea Therapeutics","has_results":false},{"nct_id":"NCT03392051","title":"Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Akcea Therapeutics","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}